Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | ACE | P12821 | 5/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7229378 | 1.00 | AGTR2 (0.51) | AGTR2PDE4BPTPN1ACEPDE3A | |
| SCHEMBL6651228 | 0.88 | PTPN1 (0.62) | AGTR2PDE4BPTPN1ACEHDAC8 | |
| SCHEMBL7220969 | 0.86 | PTPN1 (0.48) | PTPN1ACEHDAC8 | |
| SCHEMBL7220966 | 0.86 | PTPN1 (0.48) | PTPN1ACEHDAC8 | |
| SCHEMBL7221395 | 0.86 | AGTR2 (0.46) | AGTR2PTPN1ACEPDE3AHDAC8 | |
| SCHEMBL7221401 | 0.86 | AGTR2 (0.46) | AGTR2PTPN1ACEPDE3AHDAC8 | |
| SCHEMBL6951953 | 0.86 | PDE4B (0.52) | AGTR2PDE4BPTPN1HDAC8 | |
| SCHEMBL9426935 | 0.85 | AGTR2 (0.56) | AGTR2PDE4BACEPDE3AOPRD1 | |
| SCHEMBL7473700 | 0.84 | HDAC8 (0.58) | PTPN1HDAC8OPRD1OPRM1 | |
| SCHEMBL7473706 | 0.84 | HDAC8 (0.58) | PTPN1HDAC8OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100371323-C | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-02-27 | — | — | CN | disclosed |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| CN-1298703-C | Cyanopyrrolidine Derivatives | TAISHO PHARMACENTICAL CO LTD (JP) | 2007-02-07 | — | — | CN | disclosed |
| EP-1746086-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| CN-1772733-A | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-05-17 | — | — | CN | disclosed |
| CN-1715269-A | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-01-04 | — | — | CN | disclosed |
| US-20040072892-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| CN-1474809-A | Cyanopyrrolidine Derivatives | ������ҩ��ʽ���� | 2004-02-11 | — | — | CN | disclosed |
| WO-2003101967-A1 | PREPARATION OF CHIRAL 1,2,3,4-TETRAHYDRO-6,7-DIALKOXY-3-ISOQUINOLINECARBOXYLIC ACID AND DERIVATIVES BY REACTING LEVODOPA WITH FORMALDEHYDE OR FORMALDEHYDE PRECURSORS | APTEX PHARMACHEM INC. (CA) | 2003-12-11 | — | — | WO | disclosed |
| US-6642384-B1 | Forming intermediate to moexipril; cyclizing levodopa with formaldehyde; protecting amine, alkylating phenols, esterifying carboxylic acid and optionally deprotecting | BRANTFORD CHEMICALS INC. (CA) | 2003-11-04 | — | — | US | disclosed |
| EP-1333025-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072892-A1 | Cyanopyrrolidine derivatives | CCR9, OPRD1, CBR1 | AGTR2 236/4885PDE4B 3933/4885PTPN1 1331/4885 |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | DPP4, DPP9, DPP3 | AGTR2 128/4885PDE4B 375/4885PTPN1 2183/4885 |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | CBR3, CBR1, TERT | AGTR2 105/4885PDE4B 4557/4885PTPN1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.